<didl:DIDL xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:didl="urn:mpeg:mpeg21:2002:02-DIDL-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS 
			 http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didmodel.xsd"><didl:Item><didl:Descriptior><didl:Statement mimeType="application/xml; charset=utf-8"><dii:Identifier xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS
		 	http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd" xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS">http://eprints.utas.edu.au/3523/</dii:Identifier></didl:Statement></didl:Descriptior><didl:Descriptior><didl:Statement mimeType="application/xml; charset=utf-8"><oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/">
        <dc:title>Lumiracoxib (Novartis)</dc:title>
        <dc:creator>Ding, C</dc:creator>
        <dc:creator>Jones, G</dc:creator>
        <dc:subject>320503 Clinical Pharmacology and Therapeutics</dc:subject>
        <dc:description>Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.</dc:description>
        <dc:date>2002</dc:date>
        <dc:type>Article</dc:type>
        <dc:type>PeerReviewed</dc:type>
        <dc:format>application/pdf</dc:format>
        <dc:identifier>http://eprints.utas.edu.au/3523/1/lumiracoxib.pdf</dc:identifier>
        <dc:relation>http://www.biomedcentral.com/1369-7056/5?issue=12</dc:relation>
        <dc:identifier>Ding, C and Jones, G (2002) Lumiracoxib (Novartis). IDrugs, 5 (12). pp. 1168-1172. ISSN 1369-7056</dc:identifier>
        <dc:relation>http://eprints.utas.edu.au/3523/</dc:relation></oai_dc:dc></didl:Statement></didl:Descriptior><didl:Component><didl:Descriptior><didl:Statement mimeType="application/xml; charset=utf-8"><dii:Identifier xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS
		 	    http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd" xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS">http://eprints.utas.edu.au/3523/1/</dii:Identifier></didl:Statement></didl:Descriptior><didl:Resource ref="http://eprints.utas.edu.au/3523/1/lumiracoxib.pdf"></didl:Resource></didl:Component></didl:Item></didl:DIDL>